Incyte (LTS:0J9P) Other Long-Term Liabilities : $311 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Incyte Other Long-Term Liabilities?

Incyte's other long-term liabilities for the quarter that ended in Sep. 2024 was $311 Mil.

Incyte's quarterly other long-term liabilities declined from Mar. 2024 ($316 Mil) to Jun. 2024 ($299 Mil) but then increased from Jun. 2024 ($299 Mil) to Sep. 2024 ($311 Mil).

Incyte's annual other long-term liabilities increased from Dec. 2021 ($277 Mil) to Dec. 2022 ($284 Mil) and increased from Dec. 2022 ($284 Mil) to Dec. 2023 ($323 Mil).

Incyte Other Long-Term Liabilities Historical Data

The historical data trend for Incyte's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Other Long-Term Liabilities Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Incyte Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Incyte Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Incyte Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Incyte's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

INCY:USA INCY:Mexico 1INCY:Italy ICY:Germany ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines